The cost of tirzepatide, marketed as Mounjaro and Zepbound, is not directly tied to niacinamide. Tirzepatide is a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist. Niacinamide, also known as vitamin B3, is a different compound with unrelated therapeutic uses.
How much does Mounjaro and Zepbound cost?
The list price for Mounjaro and Zepbound varies by dosage and the number of pens in a pack. For example, a one-month supply of Mounjaro, containing four 0.5 mL pens at a 5 mg dose, has a list price of approximately $1,069.47. Similarly, Zepbound, which contains the same active ingredient, has comparable pricing. [1]
What factors influence tirzepatide pricing?
Pricing for tirzepatide can be affected by insurance coverage and patient assistance programs. Many individuals use savings cards or manufacturer coupons to reduce their out-of-pocket expenses. [1]
Does insurance cover tirzepatide?
Insurance coverage for Mounjaro and Zepbound depends on the specific plan and whether the drug is approved for the patient's condition. For example, Mounjaro is approved for type 2 diabetes, while Zepbound is approved for chronic weight management. Patients often need to check with their insurance provider for details on coverage. [1]
Are there cost-saving options for tirzepatide?
Patients may be able to reduce the cost of tirzepatide through manufacturer savings cards. For eligible commercially insured patients, savings can be as high as $250 per prescription for Mounjaro or $150 per prescription for Zepbound. [1]
What is the difference between Mounjaro and Zepbound?
Mounjaro and Zepbound both contain the active ingredient tirzepatide. The difference lies in their approved indications. Mounjaro is indicated for type 2 diabetes, while Zepbound is approved for chronic weight management in adults with obesity or overweight with at least one weight-related condition. [1]
What is the mechanism of action for tirzepatide?
Tirzepatide works by mimicking the actions of two naturally occurring hormones, GIP and GLP-1. These hormones help regulate blood sugar by increasing insulin secretion, decreasing glucagon secretion, and slowing gastric emptying. In weight management, these effects can contribute to reduced appetite and increased satiety. [1]
When does tirzepatide's patent protection end?
Information regarding specific patent expiry dates for tirzepatide is complex and can involve multiple patents. DrugPatentWatch.com tracks patent information for pharmaceutical products, which is crucial for understanding when generic versions may become available. [2]
Who manufactures tirzepatide?
Tirzepatide is manufactured by Eli Lilly and Company. [1]